ClinicalTrials.gg
CompletedNCT07842068Updated Sep 25, 2026

Artificial Intelligence (AI) - Based Models for Biomarkers Prediction

An observational study in Early Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Hellenic Cooperative Oncology Group · Observational

How we know

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,648
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.

Enrollment
2nd of 14
3,648 · median 423
Started
1996
with 2 others
Observational
14 of 18
3 open now
Registered
18th of 18
by date

Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 2nd largest by enrollment of the 14 observational ones that give a count, is one of 3 that started in 1996, is one of 14 observational ones, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, or all of them as a file.
02

Study summary

Despite the improvements in therapeutic approaches, breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide. Breast cancer treatment decisions are based mainly on the presence or absence of established prognostic and predictive biomarkers, mainly the hormone receptors, estrogen (ER) and progesterone (PgR), the human epidermal growth factor receptor 2 oncoprotein (HER2) in correlation with ki67 proliferation index.

Currently, PCR-based assays, next-generation sequencing (NGS), and immunohistochemistry (IHC), followed by in situ hybridization (ISH) when needed, are used for biomarker testing. Ιn an effort to overpass technical limitations, human subjectivity which may yield different results between different observers leading to inappropriate treatment and complications that can adversely affect patient quality of life, alternative, cost-effective approaches using AI-based digital pathology analysis of histopathology images has received significant attention last years. Digital pathology uses whole-slide image scanners and combined with artificial intelligence (AI) algorithms intend to improve diagnostic accuracy, enabling rapid patient stratification and optimal treatment regimens, thereby improving patient outcomes. Identification of invasive breast tumors and lymph node metastasis, evaluation of hormonal status, breast cancer grading and mitotic count evaluation, biomarkers identification based on images of the tumor microenvironment have also been enhanced by AI quantitative analysis. AI has promising results so far. More studies are, however, needed in order to overcome obstacles and before it is validated for patient care in the clinical setting.

DL technology has been implemented in clinical pathology in an attempt to automate the way pathologists evaluate hematoxylin and eosin (H/E) stained slides, but also to attain information such as molecular background and protein expression, given that genetic variations could likely be reflected in the morphology of cancer cells, and although not detectable to the human eye, these changes can be recognized by advanced DL algorithms and then correlated with a specific molecular variation or protein expression.

For the purpose of our study, we will use FFPE tumor blocks from patients enrolled in 7 randomized and observational studies conducted by the Hellenic Cooperative Oncology Group (HeCOG) to define via NGS their underlying mutational profile. Subsequently, a DL algorithm will be trained in order to examine if any genetic alterations found in breast cancer could be detected by the DL model in H/E whole section slides, which would suggest that these variants reflect in the morphology of the cancer cells.

Accordingly, we will explore if our algorithm could be trained to identify tumor infiltrating lymphocytes (TILs) by a similar approach using the annotated by our pathologist TILs regions on the H/E slides, as despite their importance, TILs scoring seems to be differentiated among pathologists because of substantial interobserver variation. This fact raises an urgent need for the exploration of novel methods for a more accurate scoring system. Indeed, the International Immuno-Oncology Working Group suggested a computational assessment of TILs based on deep learning models. The evaluation of biomarkers related to TILs, such as CD8, in IHC-stained images has also shown significant potential when DL approaches are used, yielding promising results in no biased TILs evaluation and providing us with valuable details about their distribution and spatial relationships .

Since there are still limitations and things to enhance and more data and parameters need to be incorporated to create more accurate and powerful models, we aim to improve TILs evaluation and therapeutic response prediction in breast cancer, through our deep learning model with the use of H/E whole slide images and digitalized IHC-stained CD8 images for lymphocytes' automatic detection for better quantification of immune response.

Additionally, and apart from ER and PgR IHC-stained slides digitalization, we intend also to digitalize our archive's breast cancer IHC sections stained with HER2 ab, which have already been evaluated by our experienced pathologist, as well as HER2/TOP2A/CEN17 FISH slides. Subsequently, we intend to develop an automated deep learning (DL) - based image analysis algorithm with the ultimate goal of HER2 evaluation with a more accurate than human scoring manner, with the advantage of scoring every cell within a sample specifically to better identify patients with low-level HER2 expression given that T-DXd seems to be efficacious in this patient population . In this way, we will improve diagnostic accuracy by enabling pathologists to review high-resolution digital slides, apply advanced image analysis algorithms, and reduce inter-observer variability, for an accurate HER2 expression in breast cancers.

Read the detailed description

From 1996 until 2020, 5.320 eligible patients with operable breast cancer were treated, within the context of 3 randomized and 4 observational clinical studies with dds-CT including taxanes and anthracyclines Adjuvant hormonal and radiation treatment were administered, as indicated (Table 1).

All patients have signed a study-specific written informed consent before randomization, consenting for the trial and permitting the use of their biological material for future research purposes. All studies were conducted in accordance with the Declaration of Helsinki.

IHC and FiSH data from patients enrolled in the above randomized phase III trials conducted by the Hellenic Cooperative Oncology Group (HeCOG) will be retrospectively reviewed.

Briefly, tumor material is examined mainly on tissue microarrays (TMA). Although, there is a HER2 assessment from local pathology laboratories, all tumors are re-evaluated centrally for ER, PgR and HER2 according to ASCO/CAP guidelines. Tumors are subtyped with immunohistochemistry (IHC4) for ER, PgR, HER2 and Ki67. FISH is performed for the assessment of HER2 gene status. IHC for EGFR and CK5 is used for the classification of basal-like tumors; the expression of CD8 on TILs is also evaluated. Moreover, we investigate the mutational profile of Greek women with breast cancer, via the application of DNA Next Generation Sequencing (NGS) technologies, relative also to patient outcome. All H\&E and IHC-stained slides will be digitalized for the investigation of the potential of a deep learning-based system for automated biomarker prediction.

Patient demographic, clinicopathological and treatment data are available in all cases.

03

Conditions studied

  • Early Breast Cancer

Browse trials for

Keywords

  • Artificial Intelligence model
  • FISH images
  • digitalised H/E slides
  • digitalised IHC slides
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with operable breast cancer treated with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and above
  • confirmed BC
  • All treated with dose-dense sequential chemotherapy (dds-CT)
  • Tumor tissue specimen (FFPE) availability

Exclusion criteria

Exclusion Criteria:

  • not adequate, and unsuitable tissue for IHC, FISH and analysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,648 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Development and Evaluation of an AI-based predictive algorithm

    Evaluation of the efficiency of the AI-predictive algorithm, by determining key metrics such as sensitivity and specificity

    Time frame: Through study completion, 2 years

Secondary outcomes

  1. Development of an AI-predictive algorithm from H/E and IHC digitalized slides

    All H\&E and IHC-stained slides will be digitalized for the investigation of the potential of a deep learning-based system for automated biomarker prediction

    Time frame: Through study completion, 2 years

  2. Development of an AI-based algorithm from FISH images

    An AI-based algorithm will be developed from FISH images to assess spatial patterns and cell-to-cell heterogeneity in breast cancer samples

    Time frame: Through study completion, 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Vandenberghe ME, Scott ML, Scorer PW, Soderberg M, Balcerzak D, Barker C. Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer. Sci Rep. 2017 Apr 5;7:45938. doi: 10.1038/srep45938. PubMed 28378829 ↗
  • Soliman A, Li Z, Parwani AV. Artificial intelligence's impact on breast cancer pathology: a literature review. Diagn Pathol. 2024 Feb 22;19(1):38. doi: 10.1186/s13000-024-01453-w. PubMed 38388367 ↗
  • Saldanha OL, Loeffler CML, Niehues JM, van Treeck M, Seraphin TP, Hewitt KJ, Cifci D, Veldhuizen GP, Ramesh S, Pearson AT, Kather JN. Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology. NPJ Precis Oncol. 2023 Mar 28;7(1):35. doi: 10.1038/s41698-023-00365-0. PubMed 36977919 ↗
  • Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012 Aug;135(1):301-6. doi: 10.1007/s10549-012-2143-0. Epub 2012 Jul 3. PubMed 22752290 ↗
  • Fiorin A, Lopez Pablo C, Lejeune M, Hamza Siraj A, Della Mea V. Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets. J Imaging Inform Med. 2024 Dec;37(6):2996-3008. doi: 10.1007/s10278-024-01043-8. Epub 2024 May 28. PubMed 38806950 ↗
  • El Nahhas OSM, van Treeck M, Wolflein G, Unger M, Ligero M, Lenz T, Wagner SJ, Hewitt KJ, Khader F, Foersch S, Truhn D, Kather JN. From whole-slide image to biomarker prediction: end-to-end weakly supervised deep learning in computational pathology. Nat Protoc. 2025 Jan;20(1):293-316. doi: 10.1038/s41596-024-01047-2. Epub 2024 Sep 16. PubMed 39285224 ↗
  • El Nahhas OSM, Loeffler CML, Carrero ZI, van Treeck M, Kolbinger FR, Hewitt KJ, Muti HS, Graziani M, Zeng Q, Calderaro J, Ortiz-Bruchle N, Yuan T, Hoffmeister M, Brenner H, Brobeil A, Reis-Filho JS, Kather JN. Author Correction: Regression-based Deep-Learning predicts molecular biomarkers from pathology slides. Nat Commun. 2024 Feb 29;15(1):1868. doi: 10.1038/s41467-024-46298-5. No abstract available. PubMed 38424093 ↗
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. PubMed 30207593 ↗
  • Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudecek J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020 May 12;6:16. doi: 10.1038/s41523-020-0154-2. eCollection 2020. PubMed 32411818 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 1996 to primary completion in Jul 2026, 355 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 25, 2026
StartActual
Dec 10, 1996
Primary completionActual
Jul 23, 2026
CompletionActual
Jul 23, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842068
Lead sponsor
Hellenic Cooperative Oncology Group
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Dec 10, 1996
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion